Maxpro Capital Acquisition (JMAC) Competitors $8.40 +0.24 (+2.94%) As of 03/27/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsSEC FilingsTrendsBuy This Stock JMAC vs. ORKA, PRTC, ERAS, SNDL, PHAT, GLUE, RGNX, SIGA, MREO, and HUMAShould you be buying Maxpro Capital Acquisition stock or one of its competitors? The main competitors of Maxpro Capital Acquisition include Oruka Therapeutics (ORKA), PureTech Health (PRTC), Erasca (ERAS), SNDL (SNDL), Phathom Pharmaceuticals (PHAT), Monte Rosa Therapeutics (GLUE), REGENXBIO (RGNX), SIGA Technologies (SIGA), Mereo BioPharma Group (MREO), and Humacyte (HUMA). These companies are all part of the "pharmaceutical products" industry. Maxpro Capital Acquisition vs. Oruka Therapeutics PureTech Health Erasca SNDL Phathom Pharmaceuticals Monte Rosa Therapeutics REGENXBIO SIGA Technologies Mereo BioPharma Group Humacyte Oruka Therapeutics (NASDAQ:ORKA) and Maxpro Capital Acquisition (NASDAQ:JMAC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, risk, dividends, earnings, profitability, valuation, media sentiment, institutional ownership and analyst recommendations. Which has preferable valuation & earnings, ORKA or JMAC? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOruka TherapeuticsN/AN/A-$5.34M-$5.79-2.05Maxpro Capital AcquisitionN/AN/AN/AN/AN/A Does the MarketBeat Community believe in ORKA or JMAC? Oruka Therapeutics received 17 more outperform votes than Maxpro Capital Acquisition when rated by MarketBeat users. CompanyUnderperformOutperformOruka TherapeuticsOutperform Votes17100.00% Underperform VotesNo VotesMaxpro Capital AcquisitionN/AN/A Does the media favor ORKA or JMAC? In the previous week, Maxpro Capital Acquisition had 1 more articles in the media than Oruka Therapeutics. MarketBeat recorded 2 mentions for Maxpro Capital Acquisition and 1 mentions for Oruka Therapeutics. Oruka Therapeutics' average media sentiment score of 1.89 beat Maxpro Capital Acquisition's score of 0.00 indicating that Oruka Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Oruka Therapeutics Very Positive Maxpro Capital Acquisition Neutral Do institutionals & insiders have more ownership in ORKA or JMAC? 56.4% of Oruka Therapeutics shares are owned by institutional investors. Comparatively, 73.2% of Maxpro Capital Acquisition shares are owned by institutional investors. 22.7% of Oruka Therapeutics shares are owned by insiders. Comparatively, 19.3% of Maxpro Capital Acquisition shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has more volatility & risk, ORKA or JMAC? Oruka Therapeutics has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500. Comparatively, Maxpro Capital Acquisition has a beta of 0.01, meaning that its stock price is 99% less volatile than the S&P 500. Is ORKA or JMAC more profitable? Maxpro Capital Acquisition's return on equity of 0.00% beat Oruka Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Oruka TherapeuticsN/A -24.96% -21.22% Maxpro Capital Acquisition N/A N/A N/A Do analysts rate ORKA or JMAC? Oruka Therapeutics presently has a consensus price target of $39.86, indicating a potential upside of 236.21%. Given Oruka Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Oruka Therapeutics is more favorable than Maxpro Capital Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oruka Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.22Maxpro Capital Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryOruka Therapeutics beats Maxpro Capital Acquisition on 8 of the 12 factors compared between the two stocks. Remove Ads Get Maxpro Capital Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for JMAC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart JMAC vs. The Competition Export to ExcelMetricMaxpro Capital AcquisitionHolding Offices IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$112.80M$446.37M$2.10B$8.00BDividend YieldN/A7.51%2.65%4.01%P/E RatioN/A2.2223.5918.89Price / SalesN/A60.7178.0692.98Price / CashN/A69.01N/A34.64Price / BookN/A3.611.944.30Net IncomeN/A$35.22M-$389.14M$247.06M7 Day Performance-19.15%2.42%-0.76%-0.62%1 Month Performance29.23%0.38%-2.32%-4.26%1 Year Performance1,288.43%20.98%5.55%0.61% Maxpro Capital Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)JMACMaxpro Capital AcquisitionN/A$8.40+2.9%N/A+1,311.8%$112.80MN/A0.002,021Gap UpORKAOruka Therapeutics3.211 of 5 stars$11.31-1.4%$39.86+252.4%N/A$423.46MN/A-1.81N/APositive NewsPRTCPureTech Health1.5399 of 5 stars$17.55-4.3%$45.00+156.5%-34.6%$420.09M$3.33M0.00100Gap DownERASErasca3.6602 of 5 stars$1.46+1.0%$4.90+236.8%-24.8%$411.37MN/A-1.75120Analyst ForecastNews CoverageSNDLSNDL3.611 of 5 stars$1.56-2.8%$3.25+109.0%-31.2%$408.62M$911.22M-5.02580PHATPhathom Pharmaceuticals3.6075 of 5 stars$5.85+5.5%$22.17+279.2%-39.5%$407.38M$55.25M-1.03110GLUEMonte Rosa Therapeutics2.9993 of 5 stars$6.62-0.7%$15.25+130.4%-25.3%$406.90M$14.98M-3.6290Short Interest ↓RGNXREGENXBIO4.5059 of 5 stars$8.23+5.5%$33.88+311.7%-64.3%$406.52M$83.33M-1.63370Analyst RevisionSIGASIGA Technologies2.5817 of 5 stars$5.65-1.9%N/A-34.5%$403.98M$138.72M4.7140Positive NewsMREOMereo BioPharma Group2.2394 of 5 stars$2.59+2.4%$7.83+202.4%-19.7%$401.05M$1M0.0040Earnings ReportAnalyst ForecastNews CoverageHUMAHumacyte2.1599 of 5 stars$3.13+0.1%$13.71+337.6%-35.2%$394.57M$1.57M-2.34150Earnings ReportUpcoming EarningsAnalyst ForecastNews CoverageGap Up Remove Ads Related Companies and Tools Related Companies ORKA Competitors PRTC Competitors ERAS Competitors SNDL Competitors PHAT Competitors GLUE Competitors RGNX Competitors SIGA Competitors MREO Competitors HUMA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:JMAC) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredNow that Trump’s be inaugurated, this day will be key (mark your calendar)Mark your calendar for May 7th. Because on that day, I believe we could see a $2 Trillion shock INTO the ma...Timothy Sykes | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Maxpro Capital Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Maxpro Capital Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy JMAC Stock Free JMAC Stock Alerts